-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Downgrades Kymera Therapeutics to Sector Perform, Raises Price Target to $115

Benzinga·07/13/2026 14:08:49
Listen to the news
RBC Capital analyst Brian Abrahams downgrades Kymera Therapeutics (NASDAQ:KYMR) from Outperform to Sector Perform and raises the price target from $106 to $115.